TABLE 5.
Cost of Biomarker Testing in Patients with ≥1 Biomarker Testing Procedure
| Total Population (N = 675) | Previously Diagnosed Patients (n = 80) | Newly Diagnosed Patients (n = 595) | |
|---|---|---|---|
| Total cost per patient, $ | |||
| Copaya | |||
| All patients, n | 675 | 80 | 595 |
| Mean (SD) | 43 (229) | 34 (147) | 44 (238) |
| Median | 0 | 0 | 0 |
| Erlotinib recipients, n | 634 | 80 | 554 |
| Mean (SD) | 42 (228) | 34 (147) | 43 (238) |
| Median | 0 | 0 | 0 |
| Crizotinib recipients, n | 41 | 0 | 41 |
| Mean (SD) | 55 (243) | NA | 55 (243) |
| Median | 0 | NA | 0 |
| Net payb | |||
| All patients, n | 675 | 80 | 595 |
| Mean (SD) | 891 (1,062) | 827 (932) | 900 (1,079) |
| Median | 551 | 395 | 599 |
| Erlotinib recipients, n | 634 | 80 | 554 |
| Mean (SD) | 906 (1,084) | 827 (932) | 917 (1,105) |
| Median | 549 | 395 | 600 |
| Crizotinib recipients, n | 41 | 0 | 41 |
| Mean (SD) | 664 (576) | NA | 664 (576) |
| Median | 563 | NA | 563 |
| Cost per patient by no. of biomarker testing procedures, $ | |||
| 1 procedure, n | 614 | 73 | 541 |
| Copay | |||
| Mean (SD) | 43 (236) | 34 (153) | 45 (245) |
| Median | 0 | 0 | 0 |
| Net pay | |||
| Mean (SD) | 819 (932) | 845 (946) | 816 (931) |
| Median | 513 | 400 | 524 |
| 2 procedures, n | 56 | 7 | 49 |
| Copay | |||
| Mean (SD) | 38 (159) | 27 (60) | 40 (169) |
| Median | 0 | 1 | 0 |
| Net pay | |||
| Mean (SD) | 1,640 (1,854) | 635 (807) | 1,784 (1,921) |
| Median | 1,317 | 241 | 1,384 |
| 3 procedures, n | 5 | 0 | 5 |
| Copay | |||
| Mean (SD) | 0 | NA | 0 |
| Median | 0 | NA | 0 |
| Net pay | |||
| Mean (SD) | 1,368 (764) | NA | 1,368 (764) |
| Median | 1,608 | NA | 1,608 |
Note: Cost and SD are rounded to the nearest whole number.
a Copay corresponds to the cost in patient perspective.
b Net pay corresponds to the cost in payer perspective.
NA = not applicable; SD = standard deviation.